EndoQuest Robotics, a pioneering leader in endoluminal robotic surgical technology, announced it has successfully closed a Series D-2 financing round.

This strategic funding will fuel the advancement of EndoQuest's flexible endoluminal surgical platform, supporting the ongoing pivotal PARADIGM clinical trial and accelerating the pathway towards U.S. FDA clearance, as well as early feasibility studies in the upper GI tract and progression of advanced endoluminal visualization technologies in the Company's portfolio.

Funding for the round was co-led by Crescent Enterprises and Dr. Fred Moll. Other investors in the round included Puma Venture Capital and The University of Texas Health Science Center at Houston (UTHealth Houston).